Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 8:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 149 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Painful Diabetic Peripheral Neuropathy Clear all

Conditions: Diabetic Peripheral Neuropathy
Interventions: NYX-2925, Placebo; Drug
Lead sponsor: Aptinyx; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 35
States / cities: Phoenix, Arizona • Anaheim, California • Fresno, California + 29 more

Conditions: Diabetic Peripheral Neuropathy
Interventions: Mazisotine, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 34
States / cities: Chandler, Arizona • Scottsdale, Arizona • Tucson, Arizona + 30 more

Conditions: Neuropathy, Diabetic, Neuropathy;Peripheral, Neuropathy, Painful
Interventions: Erchonia® EVRL™, Placebo Laser; Device
Lead sponsor: Erchonia Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 4
States / cities: Phoenix, Arizona • West Covina, California • Dunedin, Florida + 1 more

Conditions: Diabetic Peripheral Neuropathic Pain
Interventions: CBD, Placebo; Drug
Lead sponsor: Pure Green; Industry
Eligibility: 21 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Bloomfield Township, Michigan

Conditions: Diabetes, Peripheral Neuropathy, Pain
Interventions: lidocaine, Placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Diabetic Neuropathy, Painful
Interventions: AGN 203818, placebo capsule; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Diabetic Neuropathy Peripheral
Interventions: Active Provant Therapy System, Inactive (sham) Provant Therapy System; Device
Lead sponsor: Regenesis Biomedical, Inc.; Industry
Eligibility: 22 Years to 80 Years
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 18
States / cities: Mesa, Arizona • Northridge, California • Sacramento, California + 15 more

Conditions: Diabetic Neuropathy, Pain, Peripheral Neuropathy
Interventions: Precision Spinal Cord Stimulation; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Diabetic Peripheral Neuropathic Pain
Interventions: Suzetrigine, Placebo (matched to SUZ); Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 734 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 75
States / cities: Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 71 more

Conditions: Painful Diabetic Neuropathy (PDN), Diabetic Nephropathies
Interventions: Cognitive Behavioral Therapy (CBT), Oral Medication, Topical Medication; Device · Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 23
States / cities: Stanford, California • Jacksonville, Florida • Chicago, Illinois + 17 more

Conditions: Peripheral Neuropathy, Neuropathic Pain
Interventions: ADL5859, Duloxetine, Placebo; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 75 Years
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 27
States / cities: Riverside, California • Torrance, California • Kissimmee, Florida + 21 more

Conditions: Peripheral Diabetic Neuropathy, Painful Diabetic Neuropathy
Interventions: Capsaicin 8%; Drug
Lead sponsor: Averitas Pharma, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 10
States / cities: Wilmington, Delaware • Gainesville, Georgia • Jasper, Georgia + 7 more

Conditions: Neuropathic Pain, Distal Sensory Polyneuropathy
Interventions: LY3848575, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 24
States / cities: Chandler, Arizona • Phoenix, Arizona • Fresno, California + 20 more

Conditions: Pain, Diabetic Neuropathy
Interventions: Neurodex; Drug
Lead sponsor: Avanir Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 44
States / cities: Mesa, Arizona • Sun City, Arizona • Hot Springs, Arkansas + 39 more

Conditions: Diabetic Peripheral Neuropathy, Diabetic Peripheral Neuropathic Pain
Interventions: Moderate Cycling, Personalized Tourniquet System; Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Neuropathy, Diabetic
Interventions: Placebo, GEn 1200mg/day, GEn 2400mg/day, GEn 3600mg/day, Pregabalin; Drug
Lead sponsor: XenoPort, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 90
States / cities: Alabaster, Alabama • Birmingham, Alabama • Dothan, Alabama + 81 more

Conditions: Diabetic Neuropathy, Chemotherapy Induced Neuropathy, HIV Neuropathy, Trauma Induced Neuropathy
Interventions: Neuron012703 (Medical Food); Drug
Lead sponsor: Targeted Medical Pharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Painful Diabetic Peripheral Neuropathy
Interventions: ricolinostat, Placebo; Drug
Lead sponsor: Regenacy Pharmaceuticals LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 35
States / cities: Anniston, Alabama • Phoenix, Arizona • Huntington Beach, California + 30 more

Conditions: Painful Diabetic Neuropathy, Diabetic Neuropathy, Neuropathy
Interventions: Clonidine Gel 0.1%, Placebo; Drug
Lead sponsor: BioDelivery Sciences International; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 23
States / cities: Phoenix, Arizona • Santa Monica, California • Walnut Creek, California + 20 more

Conditions: Pain
Interventions: Oxymorphone; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetic Peripheral Neuropathy
Interventions: IMX-150, Placebo; Drug
Lead sponsor: Procris Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 7
States / cities: Brooksville, Florida • Jupiter, Florida • Miami, Florida + 4 more

Conditions: Painful Diabetic Neuropathy, Diabetes Mellitus
Interventions: Active: WST-057 4mL (146 mg pirenzepine free base monohydrate) topical solution, Placebo: WST-057 4mL topical solution; Drug
Lead sponsor: WinSanTor, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Diabetic Neuropathies
Interventions: pregabalin; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 53
States / cities: Tuscaloosa, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 44 more

Conditions: Diabetic Peripheral Neuropathy
Interventions: Bicifadine; Drug
Lead sponsor: XTL Biopharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Paducah, Kentucky

Search by objective public record fields.

Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain

Clinical Efficacy and Human Factors Validation Testing of the Erchonia EVRL for Providing Temporary Relief of Diabetic Peripheral Neuropathy Foot Pain

Using Cannabidiol to Treat Diabetic Peripheral Neuropathy of the Feet

Lidocaine for Diabetic Peripheral Neuropathy

Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral Neuropathy

Dual Field PEMF Therapy in Lower Extremity Painful Diabetic Distal Symmetric Peripheral Neuropathy

Spinal Cord Stimulation for Painful Diabetic Neuropathy

Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy

Modality Choice Before and After Failure for the Treatment of Painful Diabetic Neuropathy

Safety and Efficacy Study of ADL5859 in Participants With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

Observational Study to Evaluate the Efficacy of Sustained QUTENZA® Use in Painful Diabetic Peripheral Neuropathy

Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy

Safety and Efficacy of Dextromethorphan and Quinidine in the Treatment of the Pain of Diabetic Neuropathy

Exercise Induced Hypoalgesia Diabetes

A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN)

A Clinical Outcomes Study to Measure Reduction in Pain and Numbness During Administration of an Amino Acid Formulation in Subjects Diagnosed With Peripheral Neuropathy

Ricolinostat in Patients With Painful Diabetic Peripheral Neuropathy

Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Pain Associated With Diabetic Neuropathy

A Pilot Study of Switching From One Pain Medication to Another (Opioid Rotation)

IMX-150 Cream for Diabetic Neuropathy

A 12-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Painful Peripheral Neuropathy

Pregabalin vs Placebo in Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

Double Blind RCT of Bicifadine SR in Outpatients With Chronic Neuropathic Pain Associated With Diabetes